Gisens Biotech

Gisens Biotech (Gisens) is a point-of-care diagnostic company that develops and utilizes a reagent-free graphene chip biosensor with a microelectronic reader to detect biomarkers in less than five minutes. Gisens’ graphene biosensor is capable of detecting antigens at 10-fold lower concentration than conventional lateral flow assays with a 99.8% predictive value and 100% sensitivity. It also possesses an improved shelf-life compared to standard electronic sensors which, unlike graphene, are susceptible to oxidation. Their technology is validated for COVID-19 detection and is being tested in a Roche-funded pilot for their primary beachhead of at-home monitoring of chronic kidney disease.